Glisen-PM 1mg/500mg/15mg Tablet is a fixed-dose combination medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This combination targets multiple pathophysiological defects of diabetes by enhancing insulin secretion, improving insulin sensitivity, and reducing hepatic glucose production. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin release. Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and improves peripheral glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), thereby enhancing insulin action in adipose tissue, muscle, and the liver. Glisen-PM is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. The combination should be used with caution in patients with renal or hepatic impairment, and monitoring for potential adverse effects such as hypoglycemia, lactic acidosis, fluid retention, and weight gain is essential. Patient adherence to lifestyle modifications and regular monitoring of blood glucose and HbA1c levels are recommended to optimize therapeutic outcomes. This formulation offers a convenient once-daily dosing option to improve compliance in type 2 diabetes management.